Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension: Results of the TORREY Phase 2 imaging substudy